KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $17.5 billion.

  • Royalty Pharma's Non-Current Assets rose 769.14% to $17.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $66.5 billion, marking a year-over-year increase of 898.58%. This contributed to the annual value of $16.4 billion for FY2024, which is 869.04% up from last year.
  • Latest data reveals that Royalty Pharma reported Non-Current Assets of $17.5 billion as of Q3 2025, which was up 769.14% from $16.8 billion recorded in Q2 2025.
  • Royalty Pharma's 5-year Non-Current Assets high stood at $17.5 billion for Q3 2025, and its period low was $13.5 billion during Q1 2021.
  • Its 5-year average for Non-Current Assets is $15.0 billion, with a median of $14.6 billion in 2021.
  • As far as peak fluctuations go, Royalty Pharma's Non-Current Assets crashed by 785.08% in 2023, and later soared by 1501.48% in 2024.
  • Over the past 5 years, Royalty Pharma's Non-Current Assets (Quarter) stood at $14.6 billion in 2021, then dropped by 2.59% to $14.3 billion in 2022, then grew by 5.96% to $15.1 billion in 2023, then grew by 8.69% to $16.4 billion in 2024, then increased by 6.56% to $17.5 billion in 2025.
  • Its last three reported values are $17.5 billion in Q3 2025, $16.8 billion for Q2 2025, and $15.8 billion during Q1 2025.